First exclusively female TAVI study shows excellent results in women with Edwards heart valves

Edwards Lifesciences (NYSE: EW) today announced results from the RHEIA trial, the first study of its kind to focus exclusively on outcomes in women receiving transcatheteral aortic valve implantation (TAVI). Presenting the one-year results during a hotline session at the ESC 2024 Congress, researchers reported better outcomes in women receiving the Edwards SAPIEN 3 Ultra or SAPIEN 3 Ultra RESILIA heart valves compared with women receiving surgical aortic valve replacement (SAVR).

“Women are underrepresented in the diagnosis and treatment of severe aortic stenosis and this landmark study provides important insights into their treatment options,” said Dr. Hélène Eltchaninoff, Head of the Department of Cardiology at Rouen University Hospital. “The transcatheter and surgical arms achieved remarkable results and the performance of the transcatheter valves adds to the growing body of evidence on the treatment options available to women.”